REFERENCES
A French observational study describing the use of human polyvalent immunoglobulins in hematological malignancy- associated secondary immunodeficiency, Benbrahim et al.
Use of intravenous immunoglobulin in pediatric practice, Zülfikar et al.
Treatments for hematologic malignancies in contrast to those for solid cancers are associated with reduced red cell alloimmunization, Evers et al.
Red cell alloimmunization is associated with development of autoantibodies and increased red cell transfusion requirements in myelodysplastic syndrome, Signal et al.
American Society of Hematology 2019 guidelines for immune thrombocytopenia, Neunert et al.
Autoimmune Complications in Chronic Lymphocytic Leukemia (CLL), Zent et al.
Current clinical practice and challenges in the management of secondary immunodeficiency in hematological malignancies Il‐Kang Na
Dhalla F, Lucas M, Schuh A, et al. Antibody deficiency secondary to chronic lymphocytic leukemia: should patients be treated with prophylactic replacement immunoglobulin? J Clin Immunol. 2014;34(3):277–282.
Forconi F, Moss P. Perturbation of the normal immune system in patients with CLL. Blood. 2015;126(5):573–581.
Wadhwa PD, Morrison VA. Infectious complications of chronic lymphocytic leukemia. Semin Oncol 2006; 33:240.
Svensson T1, Höglund M, Cherif H. Clinical significance of serum immunoglobulin G subclass deficiency in patients with chronic lymphocytic leukemia. Scand J Infect Dis. 2013 Jul;45(7):537-42. doi: 10.3109/00365548.2013.769279. Epub 2013 Feb 21.
Best OG, Crassini K, Freeman JA, Mulligan SP; CLL Australian Research Consortium The clinical significance of hypogammaglobulinaemia and serum immunoglobulin G subclass deficiency in patients with chronic lymphocytic leukaemia (CLL). Scand J Infect Dis. 2013 Sep;45(9):729. doi: 10.3109/00365548.2013.809477. Epub 2013 Jul 5.
Andrea V, Nicolo C,Francesco C, Silvia İ, Renato Z, Francesco P, Gianpietro S, Livio T, and Carlo A. Clinical profile associated with infections in patients with chronic lymphocytic leukaemia. Protective role of immunglobulin in replacement therapy. Haematologica.2015 Dec; 100(12):E515-E-518. DOİ  10.3324/haematol.2015.126763.
Rozman C, Montserrat E, Viñolas N. Serum immunoglobulins in B-chronic lymphocytic leukemia. Natural history and prognostic significance.  Cancer 1988;61(2):279-283.
Freeman JA,Crassini KR, Best OG, Forsyth CJ, Mackinlay NJ, Han P,Stevenson W, Mulligan SP. Immunoglobulin G subclass deficiency and infection risk in 150 patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2013 Jan;54(1):99-104. doi: 10.3109/10428194.2012.706285. Epub 2012 Sep 8.
Parikh SA, Leis JF, Chaffee KG, Call TG, Hanson CA, Ding W, Chanan-Khan AA, Bowen D, Conte M, Schwager S, Slager SL, Van Dyke DL, Jelinek DF, Kay NE, Shanafelt TD. Hypogammaglobulinemia in newly diagnosed chronic lymphocytic leukemia: Natural history, clinical correlates, and outcomes.Cancer. 2015 Sep 1;121(17):2883-91. doi: 10.1002/cncr.29438. Epub 2015 Apr 30.
Davey FR, Kurec AS, Tomar RH, Smith JR. Serum immunoglobulins and lymphocyte subsets in chronic lymphocytic leukemia. Am J Clin Pathol . 1987;87:60-65.
Shvidel L, Tadmor T, Braester A, et al. Serum immunoglobulin levels at diagnosis have no prognostic significance in stage A chronic lymphocytic leukemia: a study of 1113 cases from the Israeli CLL Study Group. Eur J Haematol . 2014;93:29-33.
Levy R, Mahévas M, Galicier L, et al. Profound symptomatic hypogammaglobulinemia: a rare late complication after rituximab treatment for immune thrombocytopenia. Report of 3 cases and systematic review of the literature. Autoimmun Rev 2014; 13:1055.
Fernández Romero DS1, Torre MG, Larrauri BJ, Malbrán E, Juri MC, Malbrán A.[Rituximab and hypogammaglobulinemia].Medicina (B Aires). 2015;75(5):319-23.
K: Roberts DM1, Jones RB2, Smith RM2, Alberici F3,et al. Rituximab-associated hypogammaglobulinemia: incidence, predictors and outcomes in patients with multi-system autoimmune disease.J Autoimmun. 2015 Feb;57:60-5.)
Casulo C, Maragulia J, Zelenetz AD. Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections. Clin Lymphoma Myeloma Leuk 2013; 13:106.
Makatsori M, Kiani-Alikhan S, Manson AL, et al. Hypogammaglobulinaemia after rituximab treatment-incidence and outcomes. QJM 2014; 107:821.
Stiegler G, Sperr W, Lorber C, et al. Red cell antibodies in frequently transfused patients with myelodysplastic syndrome. Ann Hematol. 2001;80(6):330-333.
Sanz C, Nomdedeu M, Belkaid M, et al. Red blood cell alloimmunization in transfused patients with myelodysplastic syndrome or chronic myelomonocytic leukemia. Transfusion. 2013;53(4):710-715.
Novaretti MC, Sopelete CR, Velloso ER, et al. Immunohematological findings in myelodysplastic syndrome. Acta Haematol. 2001;105(1):1-6.
Prevention and management of transfusioninduced alloimmunization: current perspectives Barbara Hauck-Dlimi